EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials

Patientenberichtete Zufriedenheit mit einer Schilddrüsenhormonersatztherapie bei subklinischer Hypothyreose im höheren Lebensalter: gepoolte Analyse individueller Patient:innendaten aus zwei randomisierten kontrollierten Studien

Janneke Ravensberg iD, Rosalinde K E Poortvliet, Robert Du Puy, Nicolas Rodondi, Manuel Blum, Patricia Kearney, Vera J C McCarthy, Terry Quinn, Olaf Dekkers, Wouter Jukema, Simon Mooijaart, Jacobijn Gussekloo

Thyroid® · 2024-06 · 34 (6) · 702-712

DOI: 10.1089/thy.2023.0624 ↗

Auf einen Blick

Bei 536 älteren Erwachsenen mit subklinischer Hypothyreose unterschied sich die Behandlungszufriedenheit unter Levothyroxin nicht von Placebo. Auch in den meisten Untergruppen zeigten sich keine relevanten Unterschiede.

Fragestellung

Unterscheidet sich die Behandlungssatisfaktion älterer Erwachsener mit subklinischer Hypothyreose unter Levothyroxin im Vergleich zu Placebo?

Methode

Gepoolte Analyse individueller Patient:innendaten aus 2 randomisierten, doppelblinden, placebokontrollierten Studien bei älteren Erwachsenen mit subklinischer Hypothyreose.

Ergebnisse

536 Teilnehmende. Die globale Zufriedenheit unterschied sich nicht signifikant: mittlere Differenz −1,1 (95 %-KI −4,5 bis 2,1; p = 0,48). Auch in den anderen Bereichen der TSQM keine signifikanten Unterschiede.

Schlussfolgerung der Autor:innen

Die gepoolten Daten aus 2 RCTs zeigten keine wesentlichen Unterschiede in der Behandlungszufriedenheit zwischen Levothyroxin und Placebo bei älteren Erwachsenen mit SCH.

Kernaussagen

  • Globale Zufriedenheit: keine signifikanten Unterschiede zwischen Levothyroxin und Placebo
  • Auch Effektivität, Nebenwirkungen und Praktikabilität unterschieden sich nicht
  • Bei hoher Symptomlast wollten unter Levothyroxin mehr Personen weiterbehandeln

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Thyroid®, online erschienen am 24.06.2024. Verfasst von Janneke Ravensberg und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands. Hauptthemen laut MEDLINE: Hypothyroidism, Thyroxine, Hormone Replacement Therapy, Patient Satisfaction. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The benefit of levothyroxine treatment of subclinical hypothyroidism (SCH) is subject to debate. This study compared treatment satisfaction between older adults with SCH using levothyroxine or placebo.

Methods

We analyzed pooled individual participant data from two randomized, double-blind, placebo-controlled trials investigating the effects of levothyroxine treatment in older adults with SCH. Community-dwelling participants aged ≥65 years, with SCH (persistent thyrotropin levels 4.60–19.99 mIU/L for >3 months and normal free T4 level), were included. Intervention dose titration until thyrotropin levels normalized, with a mock dose adjustment of placebo. Treatment satisfaction was determined during the final study visit using the Treatment Satisfaction Questionnaire for Medication (TSQM), encompassing perceived effectiveness, side effects, convenience, and global satisfaction, along with the participants’ desire to continue study medication after the trial.

Results

We included 536 participants. At baseline, the median (interquartile range [IQR]) age was 74.9 (69.7–81.4) years, and 292 (55%) were women. The median (IQR) thyrotropin levels were 5.80 (5.10–7.00) mIU/L at baseline in both groups; at final visit, 4.97 (3.90–6.35) mIU/L in the placebo and 3.24 (2.49–4.41) mIU/L in the levothyroxine group. After treatment, the groups did not differ significantly in global satisfaction (mean difference [CI] −1.1 [−4.5 to 2.1], p = 0.48), nor in any other domain of treatment satisfaction. These results held true regardless of baseline thyrotropin levels or symptom burden. No major differences were found in the numbers of participants who wished to continue medication after the trial (levothyroxine 35% vs. placebo 27%), did not wish to continue (levothyroxine 27% vs. placebo 30%), or did not know (levothyroxine 37% vs. placebo 42%) ( p = 0.14). In a subpopulation with high symptom burden from hypothyroid symptoms at baseline, those using levothyroxine more often desired to continue the medication after the trial than those using placebo (mean difference [CI]: −21.1% [−35.6% to −6.5%]).

Conclusion

These pooled data from two RCTs showed no major differences in treatment satisfaction between older adults receiving levothyroxine or placebo. This finding has important implications for decision-making regarding initiating levothyroxine treatment for SCH. Our findings generally support refraining from routinely prescribing levothyroxine in older adults with SCH.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypothyroidismThyroxineHormone Replacement TherapyPatient SatisfactionHumansFemaleAgedMaleAged, 80 and overThyrotropinDouble-Blind MethodPatient Reported Outcome MeasuresTreatment Outcome

Stichwörter der Autor:innen

agedhumanspatient satisfactionrandomized controlled trialsubclinical hypothyroidismthyroxine

Substanzen

ThyroxineThyrotropin

Autor:innen und Institutionen

  • Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, Netherlands.
  • LUMC Center for Medicine for Older People, Leiden University Medical Center, Leiden, Netherlands.
  • Department of General Internal Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland.
  • School of Public Health, University College Cork, Cork, Ireland.
  • School of Nursing and Midwifery, University College Cork, Cork, Ireland.

ORCID-Profile: Janneke Ravensberg

Zitieren

APA

Ravensberg, J., Poortvliet, R. K. E., Du Puy, R., Rodondi, N., Blum, M., Kearney, P., McCarthy, V. J. C., Quinn, T., Dekkers, O., Jukema, W., Mooijaart, S., & Gussekloo, J. (2024). Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials. Thyroid®, 34(6), 702-712. https://doi.org/10.1089/thy.2023.0624

Vancouver

Ravensberg J, Poortvliet RKE, Du Puy R, Rodondi N, Blum M, Kearney P, et al. Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials. Thyroid®. 2024;34(6):702-712. doi:10.1089/thy.2023.0624

BibTeX
@article{Ravensberg2024,
  author = {Ravensberg, Janneke and Poortvliet, Rosalinde K E and Du Puy, Robert and Rodondi, Nicolas and Blum, Manuel and Kearney, Patricia and McCarthy, Vera J C and Quinn, Terry and Dekkers, Olaf and Jukema, Wouter and Mooijaart, Simon and Gussekloo, Jacobijn},
  title = {Patient-Reported Satisfaction with Thyroid Hormone Replacement Therapy for Subclinical Hypothyroidism in Older Adults: A Pooled Analysis of Individual Participant Data from Two Randomized Controlled Trials},
  journal = {Thyroid®},
  year = {2024},
  volume = {34},
  number = {6},
  pages = {702--712},
  doi = {10.1089/thy.2023.0624}
}
Kostenlos starten →